Jamile Shammo to Myelodysplastic Syndromes
This is a "connection" page, showing publications Jamile Shammo has written about Myelodysplastic Syndromes.
Connection Strength
2.194
-
Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy. Expert Rev Hematol. 2018 07; 11(7):577-586.
Score: 0.615
-
Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. Am J Med. 2012 Jul; 125(7 Suppl):S6-13.
Score: 0.406
-
An examination of educational gaps in the diagnosis and treatment of myelodysplastic syndromes. Cancer Control. 2011 Jan; 18(1):65-74.
Score: 0.366
-
Clinical roundtable monograph. MDS classification and risk stratification. Clin Adv Hematol Oncol. 2009 Jul; 7(7):S8-12.
Score: 0.330
-
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020 05 07; 135(19):1696-1703.
Score: 0.175
-
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). J Hematol Oncol. 2017 06 26; 10(1):131.
Score: 0.144
-
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010 Jan 20; 28(3):437-44.
Score: 0.085
-
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008 Jan 01; 111(1):86-93.
Score: 0.073